Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Omar Yaldo

Orthopaedic Surgery Newport Beach, CA Medical Doctor

NPI 1548610470 CMS profile 1708154

22 Corporate Plaza Dr, Newport Beach, CA 92660

Open in the dashboard

General payments

$32,831

206 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Omar Yaldo of Newport Beach, CA is reported in the CMS Open Payments database as having received $32,831 across 206 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,014 23
2024 General $5,764 70
2023 General $4,850 54
2022 General $6,669 34
2021 General $12,194 13
2020 General $276 4
2019 General $1,063 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Omar Yaldo
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Omar Yaldo were reported at $2,014. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Omar Yaldo Orthopaedic Surgery median Middle half National median
2019 $1,063 $644 $140–$2,844 $163
2020 $276 $312 $75–$1,860 $114
2021 $12,194 $520 $117–$2,495 $132
2022 $6,669 $598 $128–$2,731 $149
2023 $4,850 $461 $128–$2,264 $160
2024 $5,764 $497 $134–$2,475 $164
2025 $2,014 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arthrex, Inc. $17,451 74 payments
  2. Stryker Corporation $5,463 55 payments
  3. Mid-Atlantic Surgical Systems, LLC $3,944 32 payments
  4. Saxum Surgical, Inc. $2,420 9 payments
  5. Medwest Associates $983 3 payments
  6. Zimmer Biomet Holdings, Inc. $582 6 payments
  7. Bioventus LLC $534 6 payments
  8. MedShape, Inc. $374 2 payments
  9. Wright Medical Technology, Inc. $201 3 payments
  10. TriMed, Inc. $187 2 payments
  11. Other $692 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $10,792 2 payments
  2. Food and Beverage $9,090 170 payments
  3. Travel and Lodging $7,283 29 payments
  4. Education $5,666 5 payments
Products named General payments · program years 2019–2025
  1. PROPHECY $1,239 8 payments
  2. AUGMENT INJECTABLE $1,207 14 payments
  3. INFINITY $1,135 11 payments
  4. PROSTEP $843 9 payments
  5. INFINITY ADAPTIS $802 7 payments
  6. ORTHOLOC 2 LAPIFUSE $699 10 payments
  7. SALVATION $661 9 payments
  8. CITREFIX $397 3 payments
  9. EXOGEN ULTRASOUND BONE HEALING SYSTEM $387 5 payments
  10. DynaNail Helix, Washer, 15 mm $374 2 payments
  11. Other $3,251 51 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

231

Median for Orthopedic Surgery: 203

Drug cost

$973

Median for Orthopedic Surgery: $1,433

Branded share of claims

5.2%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 41 $304
Cephalexin Generic 48 $229
Methylprednisolone Generic 29 $138
Oxycodone Hcl Generic 37 $136
Silver Sulfadiazine Generic 21 $77
Meloxicam Generic 43 $76
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 12 $14

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 76 billing codes

Paid by Medicare

$48,329

Of which drugs: $149

Medicare patients

222

Average age 71

Services billed

986

135 women, 87 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 72%
Depression 32%
Diabetes 30%
Ischemic heart disease 23%
Osteoporosis 21%
Atrial fibrillation 19%
Chronic kidney disease 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 36 204 $149

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

206 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record